Notify me when Orbimed Advisors Llc files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Date Filed |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | 99 | $4.17B | +$540M | -$657M | -$117M | EWTX, BSX, LLY, SVA, ELVN | 13F-HR | 11/14/2025, 04:12 PM |
| Q2 2025 | 97 | $3.96B | +$362M | -$630M | -$267M | BSX, LLY, EWTX, ELVN, ISRG | 13F-HR | 8/14/2025, 04:36 PM |
| Q1 2025 | 106 | $4.15B | +$489M | -$665M | -$176M | EWTX, BSX, LLY, ELVN, ISRG | 13F-HR | 5/15/2025, 04:18 PM |
| Q4 2024 | 111 | $4.8B | +$615M | -$780M | -$164M | EWTX, SVA, BSX, LLY, ISRG | 13F-HR | 2/14/2025, 04:07 PM |
| Q3 2024 | 109 | $5.46B | +$606M | -$641M | -$35.3M | EWTX, SVA, LLY, BSX, ISRG | 13F-HR | 11/14/2024, 04:05 PM |
| Q2 2024 | 108 | $4.66B | +$364M | -$624M | -$260M | LLY, EWTX, BSX, ISRG, BIIB | 13F-HR | 8/14/2024, 04:06 PM |
| Q1 2024 | 112 | $5.07B | +$671M | -$958M | -$287M | LLY, EWTX, BSX, ISRG, BIIB | 13F-HR | 5/15/2024, 04:12 PM |
| Q4 2023 | 109 | $4.99B | +$462M | -$837M | -$375M | SVA, BIIB, LLY, BSX, ISRG | 13F-HR | 2/14/2024, 04:14 PM |
| Q3 2023 | 120 | $4.32B | +$550M | -$718M | -$168M | BSX, HUM, ISRG, BIIB, BMRN | 13F-HR | 11/14/2023, 04:14 PM |
| Q2 2023 | 119 | $5.14B | +$660M | -$484M | +$177M | ISRG, ELVN, BSX, THRX, BIIB | 13F-HR | 8/14/2023, 04:25 PM |
| Q1 2023 | 116 | $5.04B | +$741M | -$751M | -$9.54M | SVA, ELVN, BSX, HUM, BMY | 13F-HR | 5/15/2023, 04:41 PM |
| Q4 2022 | 114 | $4.88B | +$444M | -$602M | -$158M | UNH, BMY, BSX, HUM, BMRN | 13F-HR | 2/14/2023, 04:07 PM |
| Q3 2022 | 128 | $4.91B | +$677M | -$967M | -$290M | BMY, HUM, SWTX, BSX, BMRN | 13F-HR | 11/14/2022, 04:11 PM |
| Q2 2022 | 139 | $5.05B | +$263M | -$496M | -$233M | BMY, HUM, HZNP, BSX, TPTX | 13F-HR | 8/15/2022, 04:31 PM |
| Q1 2022 | 142 | $6.16B | +$688M | -$1.09B | -$402M | SWTX, HZNP, BSX, PFE, THRX | 13F-HR | 5/16/2022, 04:17 PM |
| Q4 2021 | 158 | $7.56B | +$983M | -$1.18B | -$196M | SWTX, BMY, HZNP, BSX, THRX | 13F-HR | 2/14/2022, 04:29 PM |
| Q3 2021 | 167 | $8.76B | +$1.03B | -$821M | +$208M | SWTX, PRLD, HZNP, MRK, BMY | 13F-HR | 11/15/2021, 04:05 PM |
| Q2 2021 | 156 | $9.7B | +$959M | -$637M | +$322M | SWTX, BMY, EWTX, BSX, MRK | 13F-HR | 8/16/2021, 04:14 PM |
| Q1 2021 | 153 | $10.2B | +$2.04B | -$2B | +$39.8M | SWTX, EWTX, PRLD, SPRY, HZNP | 13F-HR | 5/17/2021, 04:16 PM |
| Q4 2020 | 147 | $11.3B | +$2.22B | -$821M | +$1.4B | PRLD, SWTX, PMVP, SPRY, ABCL | 13F-HR | 2/16/2021, 04:43 PM |
| Q3 2020 | 140 | $7.83B | +$1.71B | -$696M | +$1.02B | PRLD, SWTX, PMVP, ALXN, TPTX | 13F-HR | 11/16/2020, 04:12 PM |
| Q2 2020 | 131 | $7.05B | +$1.1B | -$1.18B | -$77.6M | SWTX, TCDAQ, ALXN, ASND, PRVL | 13F-HR | 8/14/2020, 04:54 PM |
| Q1 2020 | 138 | $5.91B | +$1.47B | -$1.52B | -$46.9M | ASND, TCDAQ, ALEC, SWTX, MRK | 13F-HR | 5/15/2020, 04:25 PM |
| Q4 2019 | 132 | $6.98B | +$1.08B | -$1.06B | +$27.1M | ASND, THOR, TCDAQ, SWTX, PRVL | 13F-HR | 2/14/2020, 04:27 PM |
| Q3 2019 | 108 | $5.22B | +$523M | -$987M | -$464M | ASND, TCDAQ, BSX, ALEC, PRVL | 13F-HR | 11/14/2019, 04:09 PM |
| Q2 2019 | 119 | $6.34B | +$886M | -$954M | -$67.9M | ASND, TCDAQ, BSX, ALXN, ALEC | 13F-HR | 8/14/2019, 04:57 PM |
| Q1 2019 | 117 | $6.38B | +$1.09B | -$1.33B | -$245M | ASND, TCDAQ, CMTA, ALXN, ALEC | 13F-HR | 5/15/2019, 04:24 PM |
| Q4 2018 | 125 | $5.36B | +$655M | -$2.13B | -$1.48B | TCDAQ, ASND, BIIB, CELG, BSX | 13F-HR | 2/14/2019, 04:35 PM |
| Q3 2018 | 146 | $8.27B | +$1.04B | -$1.56B | -$518M | ALXN, TCDAQ, BIIB, VRTX, BSX | 13F-HR | 11/14/2018, 04:07 PM |
| Q2 2018 | 140 | $8.33B | +$1.46B | -$1.46B | -$6.28M | ALXN, BIIB, TCDAQ, BSX, VRTX | 13F-HR | 8/14/2018, 04:01 PM |
| Q1 2018 | 130 | $8.01B | +$1.75B | -$1.68B | +$71.1M | ALXN, REGN, VRTX, MRK, BIIB | 13F-HR | 5/15/2018, 04:14 PM |
| Q4 2017 | 130 | $7.76B | +$501M | -$2.62B | -$2.12B | BIIB, ALXN, REGN, CELG, VRTX | 13F-HR | 2/14/2018, 04:31 PM |
| Q3 2017 | 136 | $10.4B | +$1.06B | -$812M | +$247M | ALXN, BIIB, CELG, BSX, MRK | 13F-HR | 11/14/2017, 05:19 PM |
| Q2 2017 | 134 | $9.5B | +$1.46B | -$1.22B | +$241M | ALXN, CELG, BIIB, BSX, MRK | 13F-HR | 8/14/2017, 04:27 PM |
| Q1 2017 | 131 | $8.79B | +$1.03B | -$946M | +$87.9M | ALXN, BIIB, CELG, BSX, MRK | 13F-HR | 5/15/2017, 04:17 PM |
| Q4 2016 | 128 | $7.79B | +$1.21B | -$1.41B | -$202M | ALXN, BIIB, CELG, BSX, AMGN | 13F-HR | 2/14/2017, 04:25 PM |
| Q3 2016 | 134 | $8.71B | +$1.09B | -$2.6B | -$1.51B | BIIB, BSX, AMGN, ALXN, CELG | 13F-HR | 11/14/2016, 04:27 PM |
| Q2 2016 | 132 | $9.48B | +$1.19B | -$1.48B | -$293M | BSX, AMGN, ABBV, BMY, BIIB | 13F-HR | 8/15/2016, 04:16 PM |
| Q1 2016 | 138 | $9.47B | +$1.06B | -$865M | +$196M | BMY, HCA, AMGN, BSX, ABBV | 13F-HR | 5/16/2016, 04:20 PM |
| Q4 2015 | 128 | $11B | +$1.32B | -$997M | +$324M | BMY, AMGN, BSX, AGN, BIIB | 13F-HR | 2/16/2016, 04:24 PM |
| Q3 2015 | 129 | $9.89B | +$1.12B | -$1.06B | +$53.5M | BMY, HCA, AMGN, BSX, AGN | Restatement | 11/18/2015, 04:02 PM |
| Q2 2015 | 1 | $1.66M | $0 | $0 | BONE | New Holdings | 8/20/2015, 02:30 PM | |
| Q2 2015 | 125 | $11.8B | +$2.28B | -$2.06B | +$222M | BIIB, BMY, AGN, HCA, ABBV | 13F-HR | 8/14/2015, 04:22 PM |
| Q1 2015 | 125 | $11.5B | +$1.38B | -$1.44B | -$61.2M | BMY, BIIB, AMGN, B108PS, CELG | 13F-HR | 5/15/2015, 04:31 PM |
| Q4 2014 | 121 | $10.3B | +$1.03B | -$649M | +$379M | BIIB, BMY, AMGN, CELG, GILD | 13F-HR | 2/13/2015, 04:13 PM |
| Q3 2014 | 119 | $8.93B | +$1.6B | -$989M | +$608M | GILD, BIIB, BMY, AMGN, ICPT | 13F-HR | 11/14/2014, 04:15 PM |
| Q2 2014 | 116 | $8.24B | +$1.04B | -$753M | +$288M | ICPT, BMY, BIIB, ABBV, GILD | 13F-HR | 8/14/2014, 04:23 PM |
| Q1 2014 | 119 | $7.86B | +$1.21B | -$1.02B | +$190M | ICPT, GILD, BIIB, BMY, RLYP | 13F-HR | 5/15/2014, 04:26 PM |
| Q4 2013 | 110 | $6.71B | $0 | $0 | GILD, BIIB, CELG, BMY, AMGN | 13F-HR | 2/14/2014, 04:25 PM |